Literature DB >> 15163310

Postoperative calcitonin study in medullary thyroid carcinoma.

S I Ismailov1, N R Piulatova.   

Abstract

Calcitonin (CT) is a sensitive marker for medullary thyroid carcinoma. Normalization of early postoperative CT level is a favorable prognostic factor. The aim of this study was to establish the prognostic value of CT-level kinetics by preoperative tumor stage and postoperative elimination rate. Blood serum from 22 medullary thyroid carcinoma (MTC) patients without remote metastases was assayed. A commercial RIA DSL-1200 test was used to assay CT levels. Basal CT< or =42 pg/ml and stimulated CT< or =120 pg/ml were considered normal. The patients were divided into three groups according to the intensity of the postoperative CT level reduction in blood serum. Group 1 comprised patients who showed basal CT normalization within the first 2-3 days after surgery. Group 2 included those patients with slow (from 2 to 4 weeks) CT-level normalization. Group 3 included patients with CT levels that reduced within 14 days, but subsequently increased. Preoperative basal CT varies from 216 to 1654 pg/ml and depends on tumor-node-metastasis (TNM) stage. In seven patients, no basal CT decrease to normal values was observed; in five of these patients, disease recurrence was detected 2-6 months after surgery. In the group with slowly decreasing CT levels, no strong correlation between preoperative CT level and the postoperative time to normalization of basal and peak CT could be established; this may be due to the small number of patients. Our study showed that preoperative CT level depended on the disease stage. Postoperative CT elimination rate is independent of preoperative CT level. Postoperative increase in the basal or stimulated CT level is an unfavorable prognostic factor, implying disease recurrence. Copyright 2004 Society for Endocrinology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163310     DOI: 10.1677/erc.0.0110357

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  9 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  Predictive factors that influence the course of medullary thyroid carcinoma.

Authors:  Kalliopi Pazaitou-Panayiotou; Alexandra Chrisoulidou; Stylianos Mandanas; Konstantinos Tziomalos; Eleni Doumala; Frideriki Patakiouta
Journal:  Int J Clin Oncol       Date:  2013-07-06       Impact factor: 3.402

5.  Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer.

Authors:  Fernanda Andrade; Geneviève Rondeau; Laura Boucai; Rebecca Zeuren; Ashok R Shaha; Ian Ganly; Fernanda Vaisman; Rossana Corbo; Michael Tuttle
Journal:  Arch Endocrinol Metab       Date:  2019-03-21       Impact factor: 2.309

Review 6.  Biochemical Testing in Thyroid Disorders.

Authors:  Nazanene H Esfandiari; Maria Papaleontiou
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-08       Impact factor: 4.741

7.  Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution.

Authors:  Yasuhiro Ito; Akira Miyauchi; Tomonori Yabuta; Mitsuhiro Fukushima; Hiroyuki Inoue; Chisato Tomoda; Takashi Uruno; Minoru Kihara; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka
Journal:  World J Surg       Date:  2009-01       Impact factor: 3.352

8.  Metastatic medullary thyroid carcinoma: A case report.

Authors:  Mitra Niafar; Shahram Dabiri; Farshid Bozorgi; Farid Niafar; Nasrin Gholami
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

Review 9.  Cabozantinib for the treatment of metastatic medullary thyroid carcinoma.

Authors:  Nancy M Nix; Kirk Braun
Journal:  J Adv Pract Oncol       Date:  2014-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.